Jean‐Baptiste Méric

990 total citations
28 papers, 620 citations indexed

About

Jean‐Baptiste Méric is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jean‐Baptiste Méric has authored 28 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jean‐Baptiste Méric's work include Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (4 papers). Jean‐Baptiste Méric is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (4 papers). Jean‐Baptiste Méric collaborates with scholars based in France, Germany and Italy. Jean‐Baptiste Méric's co-authors include Marie‐France Bellin, Olivier Rixe, David Khayat, Roger Mouawad, Claude Soubrane, Michel Daudon, Pierre Conort, Anne Bissery, Alain Mallet and Philippe Greniér and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Jean‐Baptiste Méric

27 papers receiving 600 citations

Peers

Countries citing papers authored by Jean‐Baptiste Méric

Since Specialization

Citations

This map shows the geographic impact of Jean‐Baptiste Méric's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Baptiste Méric with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Baptiste Méric more than expected).

Fields of papers citing papers by Jean‐Baptiste Méric

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Baptiste Méric. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Baptiste Méric. The network helps show where Jean‐Baptiste Méric may publish in the future.

Co-authorship network of co-authors of Jean‐Baptiste Méric

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Baptiste Méric. A scholar is included among the top collaborators of Jean‐Baptiste Méric based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Baptiste Méric. Jean‐Baptiste Méric is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Care pathway of women with interval breast cancer in 2016, based on medico-administrative data 2021 ·Clinical Breast Cancer ·(unknown), Christine Le Bihan-Benjamin, Florence Molinié, A. Rogel, Jean‐Baptiste Méric, Norbert Ifrah, Philippe‐Jean Bousquet	2
2	Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours 2012 ·European Journal of Cancer ·Eric Van Cutsem, David Khayat, Chris Verslype, Bertrand Billemont, Sabine Tejpar, Jean‐Baptiste Méric, Karen Soussan-Lazard, Sylvie Assadourian, (unknown), Olivier Rixe	27
3	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·John P. Fruehauf, Jose Lutzky, David H. McDermott, Charles K. Brown, Jean‐Baptiste Méric, Brad Rosbrook, David R. Shalinsky, Katherine Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe	93
4	Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) 2011 ·Annals of Oncology ·Thomas Gauler, Benjamin Besse, Audrey Mauguen, Jean‐Baptiste Méric, V. Gounant, B. Fischer, Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Marjaana Tiainen, Frédéric Commo, Jean‐Charles Soria, Wilfried Eberhardt	24
5	Intensive Induction Chemotherapy without Methotrexate in Adult Patients with Localized Osteosarcoma: Results of the Institut Gustave-Roussy Phase II Trial 2010 ·Current Oncology ·Hazem Assi, G. Missenard, P. Terrier, C. Le Péchoux, Sylvie Bonvalot, D. Vanel, Jean‐Baptiste Méric, Thomas Tursz, A. Lecesne	28
6	Traitement néoadjuvant du cancer du rein 2008 ·Progrès en Urologie ·(unknown), Olivier Rixe, Jean‐Baptiste Méric, R. Renard-Penna, (unknown), Pierre Mozer, Éva Compérat, (unknown), M.O. Bitker	6
7	C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Thomas Gauler, Benjamin Besse, Jean‐Baptiste Méric, V. Gounant, (unknown), Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Jean‐Charles Soria, Wilfried Eberhardt	2
8	[Angiogenesis and renal cell carcinoma]. 2007 ·PubMed ·Bertrand Billemont, Jean‐Baptiste Méric, Hassan Izzedine, Laurent Taillade, (unknown), Olivier Rixe	12
9	[Angiogenesis targeting in gastro-intestinal cancers]. 2007 ·PubMed ·Jean‐Baptiste Méric	3
10	Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) 2007 ·Journal of Clinical Oncology ·Thomas Gauler, Benjamin Besse, Jean‐Baptiste Méric, V. Gounant, Bruce S. Fischer, Tobias R. Overbeck, Heiko Krissel, Dirk Laurent, Jean‐Charles Soria, Wilfried Eberhardt	25
11	Anémie chez les patients atteints de cancer pulmonaire 2005 ·Bulletin du Cancer ·Jean‐Baptiste Méric, Jean‐François Morère	6
12	Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy 2005 ·Current Medical Research and Opinion ·Joël S. Bloch, Olivier Rixe, Jean‐Baptiste Méric, Andrew Delgado, D. Khayat	10
13	Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study 2005 ·Melanoma Research ·Claude Soubrane, Olivier Rixe, Jean‐Baptiste Méric, David Khayat, Roger Mouawad	35
14	Helical CT evaluation of the chemical composition of urinary tract calculi with a discriminant analysis of CT-attenuation values and density 2004 ·European Radiology ·Marie‐France Bellin, (unknown), Pierre Conort, Anne Bissery, Jean‐Baptiste Méric, Michel Daudon, Alain Mallet, (unknown), Philippe Greniér	97
15	Intensive induction chemotherapy (CT) without methotrexate (MTX) in adult patients with localized osteosarcoma (LO): Updated results of the Institut Gustave Roussy phase II trial 2004 ·Journal of Clinical Oncology ·Hazem Assi, Marie‐Cécile Le Deley, G. Missenard, Philippe Terrier, C. Le Péchoux, Sylvie Bonvalot, D. Vanel, Jean‐Baptiste Méric, T Türsz, Axel Le Cesne	1
16	Management of primary anal canal adenocarcinoma: A large retrospective study from the Rare Cancer Network 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Yazid Belkacémi, Christine Berger, Philip Poortmans, (unknown), Abderrahim Zouhair, Jean‐Baptiste Méric, T.D. Nguyen, Marco Krengli, (unknown), Abdelkarim S. Allal, (unknown), Jacques Bernier, Luciano Scandolaro, René‐Olivier Mirimanoff	59
17	Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography 2003 ·Abdominal Imaging ·Marie‐France Bellin, (unknown), Jean‐Baptiste Méric	74
18	Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study 2002 ·PubMed ·Roger Mouawad, Olivier Rixe, Jean‐Baptiste Méric, David Khayat, Claude Soubrane	34
19	Cataracte radio-induite : aspects physiopathologiques, radiobiologiques et cliniques 2001 ·Cancer/Radiothérapie ·Yazid Belkacémi, E. Touboul, Jean‐Baptiste Méric, Patrice Rat, Jean‐Michel Warnet	14
20	Outcome after combined modality treatment for primary adenocarcinoma of the anal canal: a rare cancer network multicenter study 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Yazid Belkacémi, Christine Berger, P. Poortmans, A. Zouhair, Jean‐Baptiste Méric, (unknown), Thomas Nguyen, Marco Krengli, (unknown), E. Touboul	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact